<div>
  <ul>
    <li>
      <p>
        AI drug discovery startup Valo Health has entered a partnership with pharmaceutical manufacturing company Novo Nordisk to discover and develop new treatments for cardiometabolic diseases.
      </p>
    </li>
    <li>
      <p>
        The collaboration will leverage Valo's Opal Computational Platform and human-centric data to identify and validate druggable targets, develop drug candidates, and predict compound safety and efficacy. Novo Nordisk has also licensed three preclinical drug discovery programs in cardiovascular diseases from Valo.
      </p>
    </li>
    <li>
      <p>
        According to the partnership, Valo will receive an initial payment upfront, as well as a near-term milestone payment, adding up to a total of USD 60 million. Additionally, Valo has the potential to receive milestone payments and royalties for up to 11 programs, which could reach a total of USD 2.7 billion.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=166320">
      Company release
    </a>
  </p>
  <p>
    <a href="https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-valo-research-cardiometabolic-treatments-2023-09-25/">
      Reuters
    </a>
  </p>
  <p>
  </p>
</div>


AI Drug Discovery

Valo Health, an AI drug discovery startup, has teamed up with pharmaceutical manufacturing company Novo Nordisk to develop new treatments for cardiometabolic diseases. Valo will use its Opal Computational Platform and human-centric data to identify and validate druggable targets, develop drug candidates, and predict compound safety and efficacy. Novo Nordisk has also licensed three preclinical drug discovery programs from Valo. As part of the partnership, Valo will receive an initial payment and milestone payment totaling $60 million, and has the potential to receive milestone payments and royalties for up to 11 programs, totaling $2.7 billion.

All Updates

Valo Health and Novo Nordisk collaborate to research cardiometabolic treatments

Valo Health and Charles River launch new AI drug discovery platform

Valo Health acquires TARA Biosystems to create first-of-its-kind AI platform

Valo Health partners with Charles River to develop new AI drug discovery platform

Valo Health announces additional PIPE commitment